Last checked at 6 Apr 2018 07:00
Shield Therapeutics plc
("Shield" or the "Company")
Appointment of Non-Executive Director
London, UK, 6 April 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, is pleased to announce the appointment of Rolf Hoffmann, as a Non-Executive Director of the Company with immediate effect. Mr Hoffmann is currently Chairman of Biotest AG, sits on the Board of Directors of the large European biotechnology company Genmab AG and is a Director of San Francisco-based Trigemina Inc.
Rolf brings to Shield over 30 years of international pharmaceutical experience having served in several senior roles in the industry, most recently 12 years with Amgen as Senior Vice President of Commercial Operations for the United States, and before that as SVP International and Europe. He started his pharmaceutical career at Eli Lilly as a sales representative, progressing to senior positions including President of Latin America operations and General Manager in Germany. Rolf holds an MBA from the University of North Carolina, a master's degree from the University of Cologne and is Adjunct Professor at UNC Kenan-Flagler Business School.
Andrew Heath, Chairman of Shield Therapeutics, said: "I am delighted to welcome Rolf to the Board of Shield Therapeutics. His extensive experience and knowledge of the pharmaceutical industry and its key stakeholders in major markets will be helpful in defining the Company's future strategy and we look forward to Rolf playing a full and active role in these discussions and beyond."
Regulatory Disclosures
The following disclosures are required regarding Rolf's appointment pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
Full name and age: Rolf Karl Heinz Hoffmann, aged 58
Schedule of directorships and previous directorships (resigned within the last five years):
Current Directorships | Former Directorships |
Biotest AG | Amgen Australia Pty Limited |
EUSA | Amgen (Middle East) FZ LCC |
Genmab AG | Amgen (Middle East) FZ LLC |
German-American Heritage Foundation | Amgen (New Zealand) Limited |
NavBio AG | Amgen (New Zealand) Limited |
Stada AG | Amgen AB Norge |
Trigemeninia Inc. | Amgen Australia Pty Limited |
US Health Leadership Council | Amgen Australia Pty Limited New Zealand |
World Anti-Doping Agency | Amgen Europe B.V., Israel Branch |
| Amgen Filial AF Amgen Aktiebolag, Sverige |
| Amgen Inc. |
| Amgen Inc. |
| Amgen Latin America Services, S.A. de C.V. |
| Amgen Latin America Services, S.A. de C.V. |
| Amgen Mexico, S.A. de C.V. |
| Amgen Romania srl |
| Amgen S.p.A. |
| Amgen Singapore Pte, Ltd. |
| Amgen South Eastern Europe Operations S.r.l. |
| Amgen Switzerland AG Luzern Podruznica Ljubljana |
| Amgen Switzerland AG Rigas filiale |
| Amgen Switzerland AG Rigas filiale |
| Amgen Switzerland AG Slovakia |
| Amgen Switzerland AG Viliniaus filialas |
| Amgen Switzerland AG Viliniaus filialas |
| Amgen Technology Private Limited |
| Amgen Technology Private Limited |
| Amgen USA Inc. |
| Amgen USA Inc. |
| Immunex Corporation |
| Immunex Corporation |
| Immunex Rhode Island Corporation |
| Immunex Rhode Island Corporation |
| Tularik Limited |
No further disclosure is required under AIM Rule 17 and paragraph (g) to Schedule Two of the AIM Rules with respect to Rolf Hoffmann.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Dr Karl Keegan, Chief Financial Officer
Fleur Wood, Director, Investor Relations
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/ Dr Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.